Effect of age at onset on progression and mortality in Parkinson's disease
- 1 September 1989
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 39 (9) , 1187
- https://doi.org/10.1212/wnl.39.9.1187
Abstract
We examined longitudinal disability scores in 54 patients with Parkinson9s disease followed for 6 years at UCLA. We sorted data into 3 groups based on age at onset of symptoms: group A, onset under 50 years; group B, 50 to 59 years; group C, 60 years or older. There were no significant differences between groups initially. All 3 groups improved dramatically when levodopa was given, but group A showed significantly less disability in years 4, 5, and 6 than did group C. The groups did not differ with respect to side effects. To determine if age at onset affected mortality, we sorted records from 4 geographically diverse centers into the same 3 groups. Results on 359 patients followed for 3,314 person-years, covering a period of 17 years after onset of symptoms, showed that group A had the most favorable observed-to-expected mortality ratio, 1.82, compared with 2.17 and 2.20 for groups B and C respectively, but the difference was not statistically significant. Results from the disability analyses indicate that patients with onset of Parkinson9s disease under 50 years of age may have a more favorable prognosis than those whose symptoms begin in later years.This publication has 6 references indexed in Scilit:
- Rate of cell death in parkinsonism indicates active neuropathological processAnnals of Neurology, 1988
- Multi‐center study of Parkinson mortality with early versus later dopa treatmentAnnals of Neurology, 1987
- Long‐term follow‐up of early dopa treatment in Parkinson's diseaseAnnals of Neurology, 1986
- Evidence to support early levodopa therapy in Parkinson diseaseNeurology, 1981
- ParkinsonismNeurology, 1967
- PARKINSONS DISEASE - A RANDOM PROCESS1967